When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 6
- before April 202798%
Install
FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)
The odds
86%chance▲ 1
How the odds have moved
Yes: 91% on Nov 1, 86% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 86% | ▲ 1 | 82¢ | 89¢ | $1.12 | 20.00 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Mineralys Therapeutics, Lorundrostat
Search ›- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)The Manila Times RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in…
- Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call TranscriptMineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Jon Congleton - President, CEO & DirectorEric Warren - Chief Commercial OfficerAdam Levy - CFO & Secretary Greetings. Welcome to the Mineralys…
- Mineralys outlines December 22 PDUFA timeline while funding lorundrostat launch into 2028Mineralys Q3 2026 earnings call: lorundrostat launch prep, PDUFA timing, new blood pressure data, and cash runway into 2028. Earnings Call Insights: Mineralys Therapeutics (MLYS) Q3 2026 "We are now just weeks away from our PDUFA target…
- Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)Mineralys Therapeutics launches lorundrostat into a tough ASI market. Click here to read this analysis on the MLYS stock and also its upgraded rating. - Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited…
- FDA grants tentative approval to low-cost HIV shotThe potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa. US regulatorsâ approval of a cheaper HIV shot has lifted hopes in some of the worldâs poorest countries…
- Kidney Trial Results Could Change The Case For Mineralys Therapeutics StockThese data extend lorundrostat's profile into a cardiorenal population already heavily treated with multiple antihypertensive drugs, which speaks directly to real world treatment gaps in resistant hypertension and CKD care. Attention now…
- Pharma critic Bernie Sanders is set to hold major sway over FDA funding billSTAT WASHINGTON – Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration in part by empowering a major critic of…
- FDA Upgrades Recall of Gelatelli-Brand GelatoThe lot of Gelatelli coffee and vanilla gelato that was withdrawn from the market last month was flagged by the U.S. Food and Drug Administration (FDA) as a Class I recall event this week. Concerns about the potential for Listeria…
- FDA probes tumour risk tied to Novartis gene therapyTradingView FDA probes tumour risk tied to Novartis gene therapy
- FDA Recall Update: FebruaryThere were 14 recalls in the food & beverage, pet food, and drugs sectors, a 25% decrease compared with last month. The US Food & Drug Administration (FDA) recalled 14 food and beverage, pet food, and drugs products, and updated a previous…
- FDA Approves Amivantamab for Recurrent or Metastatic HNSCCFDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma. The approval was based on cohort 1 of the open-label, multicenter phase 1b/2 OrigAMI-4 trial, which…
- FlowStop Hemostatic Spray Hits 18,000 Units, Seeks FDA ClearanceSouth Korean maker INNOPHARMA designs the no-compression liquid spray for bystanders, firefighters and soldiers who reach injuries before medical care DAEGU, South Korea, Nov. 6, 2026 /PRNewswire/ -- A liquid spray lets people without…
Related markets
All fda & drugs ›Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance▼ 1
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 5 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions